December 2016
-
Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for… Read more . . .
-
Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of… Read more . . .
-
The UK’s National Institute for Health Care and Excellence (NICE) has issued a new “patient decision aid” that emphasizes that a metered dose inhaler “contains propellant, so it has a higher carbon footprint than a… Read more . . .
-
Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par… Read more . . .
-
According to Evoke Pharma, the FDA has issued a complete response letter in response to the company’s NDA for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. The PDUFA date for completion of… Read more . . .
-
Finnish particle engineering company Nanoform has named former Hovione executive Miguel Calado as Vice Chairman of the Board. In addition to having served as CFO and VP of Finance of Hovione, Calado has also been… Read more . . .
-
Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene… Read more . . .
-
Pulmatrix announced that it has signed an agreement with Cipla subsidiary Cipla Technologies (Cip Tec) that “lays the groundwork” for Cip Tec to acquire the rights to Pulmazole (PUR1900) inhaled dry powder itraconazole for the… Read more . . .
-
MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial… Read more . . .
-
3M Drug Delivery Systems will officially open a new 1,300 sq m R&D Inhalation Centre of Excellence on is Charnwood Campus in Loughborough, UK this month, the company said. According to 3M DDS, the new… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland